STMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling

References

• Cömert M, Ersoy Güneş A, Şahin F, et al. Quality of life and supportive care in multiple myeloma. Turk J Haematol. 2013;30(3):234–246. doi: 10.4274/Tjh.2012.0192
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953. doi: 10.1002/ijc.31937
   PubMed Web of Science ®Google Scholar
• Liu J, Liu W, Mi L, et al. Incidence and mortality of multiple myeloma in China, 2006–2016: an analysis of the global burden of disease study 2016. J Hematol Oncol. 2019;12(1):136. doi: 10.1186/s13045-019-0807-5
   PubMed Web of Science ®Google Scholar
• Schaapveld M, Visser O, Siesling S, et al. Improved survival among younger but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer. 2010;46(1):160–169. doi: 10.1016/j.ejca.2009.07.006
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520. doi: 10.1182/blood-2007-10-116129
   PubMed Web of Science ®Google Scholar
• Robak P, Drozdz I, Szemraj J, et al. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018;70:199–208. doi: 10.1016/j.ctrv.2018.09.001
   PubMed Web of Science ®Google Scholar
• Twombly R. First proteasome inhibitor approved for multiple myeloma. J Natl Cancer Inst. 2003;95(12):845. doi: 10.1093/jnci/95.12.845
   PubMed Web of Science ®Google Scholar
• Kubiczkova L, Pour L, Sedlarikova L, et al. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J Cell Mol Med. 2014;18(6):947–961. doi: 10.1111/jcmm.12279
   PubMed Web of Science ®Google Scholar
• Murray MY, Auger MJ, Bowles KM. Overcoming bortezomib resistance in multiple myeloma. Biochem Soc Trans. 2014;42(4):804–808. doi: 10.1042/BST20140126
   PubMedGoogle Scholar
• Pichiorri F, Suh S-S, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A. 2008;105(35):12885–12890. doi: 10.1073/pnas.0806202105
   PubMed Web of Science ®Google Scholar
• Vicari HP, Coelho-Silva JL, Pereira-Martins DA, et al. STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. Invest New Drugs. 2022;40(2):438–452. doi: 10.1007/s10637-021-01197-0
   PubMed Web of Science ®Google Scholar
• Po’uha ST, Le Grand M, Brandl MB, et al. Stathmin levels alter PTPN14 expression and impact neuroblastoma cell migration. Br J Cancer. 2020;122(3):434–444. doi: 10.1038/s41416-019-0669-1
   PubMed Web of Science ®Google Scholar
• Hassan MK, Watari H, Mitamura T, et al. P18/Stathmin1 is regulated by miR-31 in ovarian cancer in response to taxane. Oncoscience. 2015;2(3):294–308. doi: 10.18632/oncoscience.143
   PubMedGoogle Scholar
• Wang Z, He R, Xia H, et al. Knockdown of STMN1 enhances osteosarcoma cell chemosensitivity through inhibition of autophagy. Oncol Lett. 2017;13(5):3465–3470. doi: 10.3892/ol.2017.5941
   PubMed Web of Science ®Google Scholar
• Zhang R, Gao X, Zuo J, et al. STMN1 upregulation mediates hepatocellular carcinoma and hepatic stellate cell crosstalk to aggravate cancer by triggering the MET pathway. Cancer Sci. 2020;111(2):406–417. doi: 10.1111/cas.14262
   PubMed Web of Science ®Google Scholar
• Bai T, Yokobori T, Altan B, et al. High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients. Br J Cancer. 2017;116(9):1177–1185. doi: 10.1038/bjc.2017.76
   PubMed Web of Science ®Google Scholar
• He H, Li Z, Lu J, et al. Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma. Clin Transl Med. 2022;12(3):e757. doi: 10.1002/ctm2.757
   PubMed Web of Science ®Google Scholar
• Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol. 2019;59:125–132. doi: 10.1016/j.semcancer.2019.07.009
   PubMed Web of Science ®Google Scholar
• Hsu J, Shi Y, Krajewski S, et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood. 2001;98(9):2853–2855. doi: 10.1182/blood.V98.9.2853
   PubMed Web of Science ®Google Scholar
• Li N, Liu B, Wang D, et al. Preliminary study on the relationship among stem cell markers, drug resistance and PI3K signaling pathway in multiple myeloma (MM) cell. Transl Cancer Res TCR. 2020;9(5):3385–3391. doi: 10.21037/tcr-19-2116
   PubMed Web of Science ®Google Scholar
• Carlos J, Lima K, Costa-Lotufo LV, et al. AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis. Invest New Drugs. 2021;39(4):1139–1149. doi: 10.1007/s10637-021-01066-w
   PubMed Web of Science ®Google Scholar
• Greipp PR, Miguel JS, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420. doi: 10.1200/JCO.2005.04.242
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25(4):402–408. doi: 10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• Adam Z, Sčudla V, Krejčí M, et al. [Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials]. Vnitr Lek. 2013;59(1):37–58.
   PubMedGoogle Scholar
• Abidi MH, Gul Z, Abrams J, et al. Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma. J Chemother. 2012;24(3):167–172. doi: 10.1179/1973947812Y.0000000004
   PubMed Web of Science ®Google Scholar
• Maiso P, Huynh D, Moschetta M, et al. Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res. 2015;75(10):2071–2082. doi: 10.1158/0008-5472.CAN-14-3400
   PubMed Web of Science ®Google Scholar
• Bao P, Yokobori T, Altan B, et al. High STMN1 expression is associated with cancer progression and chemo-resistance in lung squamous cell carcinoma. Ann Surg Oncol. 2017;24(13):4017–4024. doi: 10.1245/s10434-017-6083-0
   PubMed Web of Science ®Google Scholar
• Li Y, Liang Y, Sang Y, et al. MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1. Cell Death Dis. 2018;9(1):14. doi: 10.1038/s41419-017-0030-7
   PubMedGoogle Scholar
• Yu W, Chen Y, Xiang R, et al. Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance. Leuk Lymphoma. 2017;58(2):428–437. doi: 10.1080/10428194.2016.1190968
   PubMed Web of Science ®Google Scholar
• Trovik J, Wik E, Stefansson I, et al. Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer. Histopathology. 2010;57(4):641–646. doi: 10.1111/j.1365-2559.2010.03661.x
   PubMed Web of Science ®Google Scholar
• Xun G, Hu W, Li B. PTEN loss promotes oncogenic function of STMN1 via PI3K/AKT pathway in lung cancer. Sci Rep. 2021;11(1):14318. doi: 10.1038/s41598-021-93815-3
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang X, Ji J, et al. Stathmin1 increases radioresistance by enhancing autophagy in non-small-cell lung cancer cells. Onco Targets Ther. 2016;9:2565–2574. doi: 10.2147/OTT.S100468
   PubMed Web of Science ®Google Scholar
• Schimmack S, Taylor A, Lawrence B, et al. Stathmin in pancreatic neuroendocrine neoplasms: a marker of proliferation and PI3K signaling. Tumour Biol. 2015;36(1):399–408. doi: 10.1007/s13277-014-2629-y
   PubMedGoogle Scholar
• Machado-Neto JA, Pericole FV, Costa FF, et al. Stathmin 1 expression in plasma cell neoplasms. Rev Bras Hematol Hemoter. 2017;39(2):183–185. doi: 10.1016/j.bjhh.2017.02.005
   PubMedGoogle Scholar